Zur Rose Group nominates Rongrong Hu as director

The Board of Directors of the Zur Rose Group has decided to propose Rongrong Hu for election as a new member at the General Meeting of Shareholders on 28 April 2022. Rongrong Hu, a 41-year-old Chinese national, has been living in Switzerland since 2016 and is an investor focusing on the technology sector. Previously she worked for eBay as Senior Director of Innovation, M&A & Business Development EMEA and Chief Strategy Officer Greater China. Before that she worked for McKinsey & Company, CITIC Capital and was the founder of various businesses. Rongrong Hu graduated with a dual Bachelor's Degree in Telecommunication Engineering and International Economics & Trading from Shanghai Jiaotong University and holds an MBA from Harvard Business School. Chairman of the Board Prof. Stefan Feuerstein said: "We are delighted to have been able to persuade Rongrong Hu to stand for our board. As a proven expert in e-commerce and technology with broad business experience, she is an ideal addition."

The Board of Directors will have a further female member as a result of the nomination of Rongrong Hu, and following the previously announced departures of Dr. Thomas Schneider and Prof. Dr. Volker Amelung at the next General Meeting of Shareholders it will shrink from seven to six members. With the election of Rongrong Hu, the Board's announced target of achieving at least 30 per cent female members by 2023 will be reached a year ahead of schedule.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: , phone: 9

Media contact
Lisa Lüthi, Head of Group Communications
Email: , phone: 4

Agenda
20 January 2022 Sales 2021
24 March 2022 2021 Full-Year Results
20 April 2022 First Quarter Trading Update
28 April 2022 Annual General Meeting

Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 1,752 million in 2020.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.